StackTerminal.Health

BETA
Alternative layoutGrade B · 84Clean

Research-only: Gut / Inflammation (KPV + BPC-157)

Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).

What this is for
General support
gut, digestion, research-only
Why you are seeing this
Goal fit: gut, digestion, research-only.
What to do next
Add body metrics if you want dose previews to reflect your weight rather than the reference dose.
← BackView current layout
Buy stack
Public•Built 06 Feb 2026•3 ingredients•No interactions detected
Core stack
The main ingredients doing the work.
3 key items
KPVLow
Daily • Other •
Preclinical colitis models; limited human translation.
Buy ingredient →
1mg
Targeted KPV delivery for ulcerative colitis (preclinical)
Low
Population: Mouse ulcerative colitis models (DSS and TNBS)
Study type: Preclinical (animal + in vitro)
Dose context: —

Hyaluronic acid-functionalized nanoparticles loaded with KPV showed targeted delivery to colonic epithelial cells & macrophages, reducing inflammation in murine UC models; translational relevance to humans is not established.

Citation: Xiao et al., Mol Ther (2017) — Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles•https://pubmed.ncbi.nlm.nih.gov/28143741/
Colitis-associated cancer prevention (preclinical)
Low
Population: Mouse models (PepT1-expressing)
Study type: Preclinical (animal)
Dose context: —

KPV transported via PepT1 reduced colitis severity & prevented carcinogenesis in murine colitis-associated cancer models; no human trials identified.

Citation: Dalmasso et al., Inflamm Bowel Dis (2016) — Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of KPV•https://pubmed.ncbi.nlm.nih.gov/27458604/
Colitis severity reduction
Low
Population: Mouse colitis models + cellular models
Study type: Preclinical (cell + mouse)
Dose context: — • Duration: Preclinical protocol (see paper)

KPV showed anti-inflammatory effects mediated by PepT1 transport in intestinal epithelial/immune cells & reduced inflammation in mouse colitis models.

Citation: Dalmasso et al., Am J Physiol Gastrointest Liver Physiol (2008) — PepT1-mediated KPV uptake and colitis models•https://pubmed.ncbi.nlm.nih.gov/18061177/
BPC-157Low
Daily • Lyophilized •
Preclinical GI models exist; robust clinical efficacy data lacking.
Buy ingredient →
1mg
Soft tissue healing signals (preclinical)
Low
Population: Animal models (multiple tissues)
Study type: Review (preclinical-focused)
Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/
Safety / pharmacokinetics
Low
Population: Healthy volunteers
Study type: Registered phase 1 trial (results not posted)
Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284
Musculoskeletal healing (preclinical)
Low
Population: Animal injury models (multiple tissues)
Study type: Narrative review of preclinical evidence
Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
Magnesium (Glycinate)Moderate
Daily • — •
Added manually
Buy ingredient →
400mg
Trade-offs & context
Tolerance

Loose stools at higher doses; glycinate form is better tolerated than citrate or oxide

Context: doses >400mg elemental

Timing

Drowsiness — take in the evening to leverage rather than fight this effect

Sleep quality in adults with poor sleep (magnesium bisglycinate RCT)
Moderate
Population: Adults aged 18–65 with self-reported poor sleep (n=155)
Study type: RCT (double-blind, placebo-controlled)
Dose context: 250 mg typical (range: 200–250 mg) • Duration: 8 weeks

250 mg elemental magnesium as bisglycinate modestly but significantly reduced Insomnia Severity Index score vs. placebo (−3.9 vs −2.3, p=0.049) by week 4; well-tolerated with minimal GI effects.

Citation: Abboud M et al. Nutrients. 2025.•https://pubmed.ncbi.nlm.nih.gov/40918053/
First RCT specifically using magnesium bisglycinate for sleep in a general adult population.
Insomnia in older adults (sleep latency, total sleep time)
Low
Population: Older adults with insomnia (3 RCTs, n=151)
Study type: Systematic review & meta-analysis
Dose context: 320 mg typical (range: 100–500 mg) • Duration: 8 weeks

Magnesium supplementation reduced sleep onset latency by ~17 min vs. placebo; increased sleep time & efficiency. Evidence rated low-to-very-low quality; all trials at moderate-to-high bias risk.

Citation: Mah J & Pitre T. BMC Complement Med Ther. 2021;21(1):125.•DOI: 10.1186/s12906-021-03297-z•https://pubmed.ncbi.nlm.nih.gov/33865376/
Benefit most plausible in those with low baseline magnesium. Dose refers to elemental magnesium.
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
3
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
KPV
Take ~30 min before the intended effect window
Reaches peak plasma concentration in ~30 min. Half-life ~1h.
BPC-157
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
Magnesium (Glycinate)
Evening (glycinate/threonate) or before bed
Magnesium promotes GABA activity and lowers core body temperature, aiding sleep onset and quality. (Onset: ~2h, half-life: ~8h)

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Similar community stacks

If this is close but not quite right, start from a similar stack rather than from zero.

Browse all community stacks →
recoveryskinresearch-only

Research-only: Recovery + Skin (GLOW-style grouping)

by@athlete

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
GHK-Cu
1mg
New
View
sleepcalmfocus

Research-only: Calm + Focus (Selank + Semax)

by@athlete

Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.

Selank
1mg
Semax
10mg
New
View
recoveryjointsresearch-only

Research-only: Recovery / Joints (BPC-157 + TB4)

by@athlete

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
New
View